Avalo Therapeutics (AVTX) CMO sells shares under 10b5-1 plan

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Avalo Therapeutics, Inc.’s Chief Medical Officer, Doyle Mittie, reported an exercise-and-sell stock transaction. On May 28, 2026, she exercised stock options to acquire 679 shares of common stock at $8.04 per share and sold 679 shares in an open-market trade at $16.00 per share.

The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 13, 2025. Following these trades, she directly holds 47,122 shares of common stock and 118,321 stock options that remain outstanding.

Insider Trade Summary 10b5-1

Net Seller: 679 shares ($10,864)

Net Sell 3 txns

Insider Doyle Mittie

Role Chief Medical Officer

Sold 679 shs ($11K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	679	$0.00	--
Exercise	Common Stock	679	$8.04	$5K
Sale	Common Stock	679	$16.00	$11K

Holdings After Transaction: Stock Option (Right to Buy) — 118,321 shares (Direct, null); Common Stock — 47,801 shares (Direct, null)

Footnotes (1)

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Shares sold: 679 shares Sale price: $16.00 per share Option exercise price: $8.04 per share +4 more

7 metrics

Shares sold 679 shares Common Stock sold on May 28, 2026 in open market

Sale price $16.00 per share Price for 679 common shares sold on May 28, 2026

Option exercise price $8.04 per share Exercise price for 679 shares from stock option

Shares after transaction 47,122 shares Common Stock directly owned following May 28, 2026 trades

Options remaining 118,321 options Stock options outstanding after the reported exercise

Option expiration January 28, 2035 Expiration date of the exercised stock option series

Net share change -679 shares Net of buys and sells according to transaction summary

Key Terms

Rule 10b5-1 trading plan, Stock Option (Right to Buy), Chief Medical Officer, open-market sale, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

Chief Medical Officer financial

"officer_title": "Chief Medical Officer""

A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Exercise or conversion of derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/01/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doyle Mittie

(Last)

(First)

(Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE

PENNSYLVANIA

19087

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/28/2026		M⁽¹⁾		679	A	$8.04	47,801	D
Common Stock	05/28/2026		S⁽¹⁾		679	D	$16	47,122	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$8.04	05/28/2026		M⁽¹⁾			679	⁽²⁾	01/28/2035	Common Stock	679	$0	118,321	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

2. The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Christopher Sullivan, Attorney-in-Fact	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Avalo Therapeutics (AVTX) report for Doyle Mittie?

Avalo Therapeutics reported that Chief Medical Officer Doyle Mittie exercised stock options and sold shares. On May 28, 2026, she exercised options for 679 common shares and sold 679 shares in an open-market transaction, as disclosed in a Form 4 insider trading report.

How many Avalo Therapeutics (AVTX) shares did Doyle Mittie sell and at what price?

Doyle Mittie sold 679 shares of Avalo Therapeutics common stock at $16.00 per share. The sale occurred on May 28, 2026 and was reported as an open-market transaction under SEC rules for insider trading disclosures.

What stock option exercise did Avalo Therapeutics (AVTX) disclose for Doyle Mittie?

Doyle Mittie exercised stock options covering 679 shares at $8.04 per share. The options were described as a Stock Option (Right to Buy), and the exercise took place on May 28, 2026 as part of the transactions reported in the Form 4.

How many Avalo Therapeutics (AVTX) shares does Doyle Mittie hold after the reported transactions?

After the reported trades, Doyle Mittie directly holds 47,122 Avalo Therapeutics common shares. In addition, she has 118,321 stock options remaining outstanding following the May 28, 2026 exercise-and-sell transaction sequence disclosed in the Form 4 filing.

Were Doyle Mittie’s Avalo Therapeutics (AVTX) transactions under a Rule 10b5-1 plan?

Yes, the Form 4 states the transactions were made under a Rule 10b5-1 trading plan. The plan was adopted on November 13, 2025, indicating the May 28, 2026 exercise and sale were pre-arranged rather than discretionary trades.